

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to The United States Patent and Trademark Office on the date set forth below.

Date Of Signature And Transmission:

Oct 29, 03

Jean C. Baker

Jean C. Baker, Reg. No. 35,433

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FACSIMILE TRANSMISSION COVER SHEET

TO: Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Telecopy No. (703) 872-9307

RECEIVED  
CENTRAL FAX CENTER

OCT 28 2003

FROM: Jean C. Baker, Esq.  
Reg. No. 35,433  
Attorney For Applicant  
Quarles & Brady LLP  
411 East Wisconsin Avenue  
Milwaukee, Wisconsin 53202  
Telephone No. (414) 277-5000  
Telecopy No. (414) 271-3552

OFFICIAL

IN CASE OF PROBLEM, CALL (414) 277-5744

DATE: October 28, 2003

Applicant: Jeffrey Ross  
Serial No.: 09/873,637  
Filed: June 4, 2001  
For: C-MYC CODING REGION DETERMINANT-BINDING PROTEIN  
(CRD-BP) AND TIS NUCLEIC ACID SEQUENCE  
Art Unit: 1642  
Examiner: M. Yu

-----  
Client Matter No: 960296.98164  
Job Code:  
No. Pages:

Appl. No. 09/873,637  
Amdt. Dated October 28, 2003  
Reply to Office Action of September 8, 2003

Listing of Claims:

Please cancel claim 23.

Claims 1 – 15 (withdrawn)/

16. (Amended) A method of detecting breast cancer ~~determining the presence or absence of anti-CRD-BP antibody in a patient's serum~~ comprising the steps ~~step~~ of:

a) exposing a patient's serum to CRD-BP and determining whether an anti-CRD-BP antibody is present.

b) correlating the presence of anti-CRD-BP antibodies with breast cancer diagnosis.

Claims 17 – 20 (withdrawn).

21. (Previously Added) The method of claim 16 wherein the CRD-BP is recombinant.

22. (Amended) The method of claim 16 wherein the amount of anti-CRD-BP antibody is quantitated.

23. (Withdrawn) The method of claim 16 additionally comprising the step of correlating anti-CRD-BP antibody presence with cancer diagnosis.

**Listing of Claims:**

Please cancel claims 1-15, 17-20, 23 and 26.

Claims 1 – 15 (cancelled)

1 ~~16.~~ (currently amended) A method of detecting breast cancer comprising the steps of:

- a) obtaining a serum sample from a patient, exposing a patient's said  
serum to human CRD-BP and determining whether an anti-CRD-BP antibody is present in  
said serum; and
- b) correlating the presence of said anti-CRD-BP ~~antibodies~~-antibody with  
presence of breast cancer.
- delete comma*

Claims 17 – 20 (cancelled).

2 ~~21.~~ (previously presented) The method of claim ~~16~~ wherein the CRD-BP is  
recombinant.

3 ~~22.~~ (previously presented) The method of claim ~~16~~ wherein the amount of anti-  
CRD-BP antibody is quantitated.

23. (cancelled)

4 ~~24.~~ (previously presented) The method of claim ~~16~~ wherein the CRD-BP is bound  
to a solid support.

5 ~~25.~~ (previously presented) The method of claim ~~24~~ wherein the CRD-BP is  
exposed to serum and anti-CRD-BP antibody in the serum binds to the CRD-BP.

26. (cancelled)

6 ~~27.~~ (currently amended) The method of claim ~~26~~ ~~24~~ wherein the CRD-BP is  
radiolabeled and exposed to the serum, wherein the amount of radiolabeled CRD-BP bound  
to the solid support is measured.